Get the Stockscreener App
0.00
100.00%
-47.98
Tourmaline Bio Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$47.98
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.23B
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
0.00
EPS:
0.5785
Net Cash Flow:
$-19.23M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$48.27
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Compare TRML with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
0.00 | 1.23B | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Nov-11-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Movement Recap: What catalysts could drive Tourmaline Bio Inc stock higherRate Cut & Precise Buy Zone Tips - BỘ NỘI VỤ
Can Tourmaline Bio Inc. stock outperform in 2025 bull marketEarnings Risk Summary & Daily Stock Trend Watchlist - moha.gov.vn
Will Tourmaline Bio Inc. stock outperform value stocksQuarterly Portfolio Review & Safe Swing Trade Setups - newser.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Is Tourmaline Bio Inc. stock attractive after correctionTrade Entry Summary & Verified Short-Term Plans - newser.com
How to manage a losing position in Tourmaline Bio Inc.Market Performance Summary & Fast Exit and Entry Trade Guides - newser.com
Will Tourmaline Bio Inc. stock reach all time highs in 2025Trade Performance Summary & Safe Swing Trade Setups - newser.com
Combining machine learning predictions for Tourmaline Bio Inc.Long Setup & Weekly Setup with ROI Potential - newser.com
How Tourmaline Bio Inc. stock performs in rate cut cyclesJuly 2025 PostEarnings & Verified Chart Pattern Signals - newser.com
Is Tourmaline Bio Inc. stock a top pick in earnings seasonAnalyst Downgrade & Smart Allocation Stock Tips - newser.com
[EFFECT] Tourmaline Bio, Inc. SEC Filing - Stock Titan
Using Bollinger Bands to evaluate Tourmaline Bio Inc.Portfolio Gains Report & Daily Technical Forecast Reports - newser.com
Tourmaline Bio Inc. recovery potential after sell offPortfolio Performance Report & Consistent Profit Focused Trading Strategies - newser.com
How institutional buying supports Tourmaline Bio Inc. stockJuly 2025 Momentum & Low Risk High Win Rate Stock Picks - Fundação Cultural do Pará
How to monitor Tourmaline Bio Inc. with trend dashboardsQuarterly Profit Review & Step-by-Step Swing Trade Plans - newser.com
Analyzing drawdowns of Tourmaline Bio Inc. with statistical toolsJobs Report & Precise Swing Trade Alerts - newser.com
Tourmaline Bio Inc.’s volatility index tracking explainedAnalyst Upgrade & Safe Investment Capital Preservation Plans - newser.com
Statistical indicators supporting Tourmaline Bio Inc.’s strength2025 Technical Overview & Weekly Watchlist for Hot Stocks - newser.com
Is Tourmaline Bio Inc. stock a smart buy before Fed meeting2025 Volatility Report & Real-Time Market Trend Scan - newser.com
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):